Hanne Verswyvel

Hanne Verswyvel

Auto-generated profile, based on publicly available information

Hanne Verswyvel

Center for Oncological Research (CORE), University of Antwerp

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in Redox Biology
Verified
Journal Article
Open access
Maksudbek YusupovMaksudbek Yusupov
Maksudbek Yusupov
Angela Privat MaldonadoAngela Privat Maldonado
Angela Privat Maldonado
RCRodrigo M. Cordeiro
Rodrigo M. Cordeiro
HVHanne Verswyvel
Hanne Verswyvel
PSPriyanka Shaw
Priyanka Shaw
Annemie  BogaertsAnnemie Bogaerts
Annemie Bogaerts
Multiple cancer therapies nowadays rely on oxidative stress to damage cancer cells. Here we investigated the biological and molecular effect of oxidative stress on the interaction between CD44 and hyaluronan (HA), as interrupting their binding can hinder cancer progression. Our experiments demonstrated that the oxidation of HA decreased its recognition by CD44, which was further enhanced when both CD44 and HA were oxidized. The reduction of CD44-HA binding negatively affected the proliferative state of cancer cells. Our multi-level atomistic simulations revealed that the binding free energy of HA to CD44 decreased upon oxidation. The effect of HA and CD44 oxidation on CD44-HA binding was similar, but when both HA and CD44 were oxidized, the effect was much larger, in agreement with our experiments. Hence, our experiments and computations support our hypothesis on the role of oxidation in the disturbance of CD44-HA interaction, which can lead to the inhibition of proliferative signaling pathways inside the tumor cell to induce cell death.

2 February 2021 in Cancers
Verified
Journal Article
Open access
PDF file
Abraham LinAbraham Lin
Abraham Lin
Jamoliddin RazzokovJamoliddin Razzokov
Jamoliddin Razzokov
HVHanne Verswyvel
Hanne Verswyvel
Angela Privat MaldonadoAngela Privat Maldonado
Angela Privat Maldonado
JBJoey De Backer
Joey De Backer
Annemie  BogaertsAnnemie Bogaerts
Annemie Bogaerts
Non-thermal plasma (NTP) therapy has been emerging as a promising cancer treatment strategy, and recently, its ability to locally induce immunogenic cancer cell death is being unraveled. We hypothesized that the chemical species produced by NTP reduce immunosuppressive surface proteins and checkpoints that are overexpressed on cancerous cells. Here, 3D in vitro tumor models, an in vivo mouse model, and molecular dynamics simulations are used to investigate the effect of NTP on CD47, a key innate immune checkpoint. CD47 is immediately modulated after NTP treatment and simulations reveal the potential oxidized salt-bridges responsible for conformational changes. Umbrella sampling simulations of CD47 with its receptor, signal-regulatory protein alpha (SIRPα), demonstrate that the induced-conformational changes reduce its binding affinity. Taken together, this work provides new insight into fundamental, chemical NTP-cancer cell interaction mechanisms and a previously overlooked advantage of present NTP cancer therapy: reducing immunosuppressive signals on the surface of cancer cells.

7 October 2022 in Redox Biology
Verified
Journal Article
Open access
MOMaria Cecilia Oliveira
Maria Cecilia Oliveira
HVHanne Verswyvel
Hanne Verswyvel
ESEvelien Smits
Evelien Smits
RCRodrigo M. Cordeiro
Rodrigo M. Cordeiro
Annemie  BogaertsAnnemie Bogaerts
Annemie Bogaerts
Abraham LinAbraham Lin
Abraham Lin
Gap junctions (GJs), essential structures for cell-cell communication, are made of two hemichannels (commonly called connexons), one on each adjacent cell. Found in almost all cells, GJs play a pivotal role in many physiological and cellular processes, and have even been linked to the progression of diseases, such as cancer. Modulation of GJs is under investigation as a therapeutic strategy to kill tumor cells. Furthermore, GJs have also been studied for their key role in activating anti-cancer immunity and propagating radiation- and oxidative stress-induced cell death to neighboring cells, a process known as the bystander effect. While, gap junction (GJ)-based therapeutic strategies are being developed, one major challenge has been the paradoxical role of GJs in both tumor progression and suppression, based on GJ composition, cancer factors, and tumoral context. Therefore, understanding the mechanisms of action, regulation, and the dual characteristics of GJs in cancer is critical for developing effective therapeutics. In this review, we provide an overview of the current understanding of GJs structure, function, and paradoxical pro- and anti-tumoral role in cancer. We also discuss the treatment strategies to target these GJs properties for anti-cancer responses, via modulation of GJ function.

28 April 2023 in Journal of Physics D: Applied Physics
Verified
Journal Article
Closed access
HVHanne Verswyvel
Hanne Verswyvel
CDChristophe Deben
Christophe Deben
AWAn Wouters
An Wouters
FLFilip Lardon
Filip Lardon
Annemie  BogaertsAnnemie Bogaerts
Annemie Bogaerts
Abraham LinAbraham Lin
Abraham Lin
Live-cell imaging with fluorescence microscopy is a powerful tool, especially in cancer research, widely-used for capturing dynamic cellular processes over time. However, light-induced toxicity (phototoxicity) can be incurred from this method, via disruption of intracellular redox balance and an overload of reactive oxygen species (ROS). This can introduce confounding effects in an experiment, especially in the context of evaluating and screening novel therapies. Here, we aimed to unravel whether phototoxicity can impact cellular homeostasis and response to non-thermal plasma (NTP), a therapeutic strategy which specifically targets the intracellular redox balance. We demonstrate that cells incorporated with a fluorescent reporter for live-cell imaging have increased sensitivity to NTP, when exposed to ambient light or fluorescence excitation, likely through altered proliferation rates and baseline intracellular ROS levels. These changes became even more pronounced the longer the cells stayed in culture. Therefore, our results have important implications for research implementing this analysis technique and are particularly important for designing experiments and evaluating redox-based therapies like NTP.

1 October 2024 in Redox Biology
Verified
Journal Article
Open access
PHPepijn Heirman
Pepijn Heirman
HVHanne Verswyvel
Hanne Verswyvel
MBMauranne Bauwens
Mauranne Bauwens
MYMaksudbek Yusupov
Maksudbek Yusupov
JWJorrit De Waele
Jorrit De Waele
ABAnnemie Bogaerts
Annemie Bogaerts
Non-thermal plasma (NTP) shows promise as a potent anti-cancer therapy with both cytotoxic and immunomodulatory effects. In this study, we investigate the chemical and biological effects of NTP-induced oxidation on several key, determinant immune checkpoints of natural killer (NK) cell function. We used molecular dynamics (MD) and umbrella sampling simulations to investigate the effect of NTP-induced oxidative changes on the MHC-I complexes HLA-Cw4 and HLA-E. Our simulations indicate that these chemical alterations do not significantly affect the binding affinity of these markers to their corresponding NK cell receptor, which is supported with experimental read-outs of ligand expression on human head and neck squamous cell carcinoma cells after NTP application. Broadening our scope to other key ligands for NK cell reactivity, we demonstrate rapid reduction in CD155 and CD112, target ligands of the inhibitory TIGIT axis, and in immune checkpoint CD73 immediately after treatment. Besides these transient chemical alterations, the reactive species in NTP cause a cascade of downstream cellular reactions. This is underlined by the upregulation of the stress proteins MICA/B, potent ligands for NK cell activation, 24 h post treatment. Taken together, this work corroborates the immunomodulatory potential of NTP, and sheds light on the interaction mechanisms between NTP and cancer cells.

4 June 2025
Verified
Thesis
Closed access
HVHanne Verswyvel
Hanne Verswyvel
The immune system remains one of the strongest defense mechanisms against cancer and immune-engaging therapies have therefore become a cornerstone of modern cancer management. However, despite clear successes, treatments like immune checkpoint inhibition (ICI) still face significant limitations, especially in solid tumors with a hostile and immune-deprived tumor microenvironment (TME). While precision medicine aims to overcome these hurdles through personalized approaches, strategies with a broad application potential still have their value, especially when they can enhance tumor immunogenicity. During my PhD, I investigated the immunomodulatory capacity of non-thermal plasma (NTP) with the purpose to incorporate it as a potent adjuvant for current treatment options. The generated reactive oxygen and nitrogen species (ROS/RNS) in NTP are reported to induce oxidative stress and immunogenic cell death (ICD), and thus hold potential to enhance tumor immunogenicity and improve both innate and adaptive immune recruitment. Before assessing therapeutic efficacy, rigorous experimental considerations were necessary. In research chapter 2, I demonstrated that fluorophore-induced phototoxicity alters intracellular redox homeostasis and increases cancer cell sensitivity to NTP, raising awareness for a major confounding factor for redox-based therapy research. This work highlights the importance of methodological optimization in fluorescence-based imaging studies, especially in the growing field of complex 3D tumor models and live-cell tracking. Building on previous research establishing NTP as a bona fide ICD inducer, I investigated in my research chapter 3 whether NTP could enhance the immunogenicity of conventional cisplatin (cis-diamminedichloroplatinum (II), CDDP) administration, a standard treatment for head and neck cancer squamous cell carcinoma (HNSCC) and many other tumor types. My findings reveal synergistic cytotoxic effects of NTP-CDDP combination therapy, with significant damage-associated molecular pattern release and cytokine modulation, underlining the robustness of the immune-stimulatory capacity of NTP. Moreover, the gold standard in vivo vaccination assay confirmed that NTP-CDDP enhances anti-tumor immunity, leading to nearly 40% protection against tumor rechallenge in a syngeneic mouse model. Despite the growing body of evidence for NTP’s immunomodulatory potential, few studies have considered relevant combination with current standard-of-care, a critical gap in the field preceding clinical introduction which was addressed here. While adaptive immunity remains a major focus in immunotherapy, innate immunity, particularly natural killer (NK) cells, play a crucial role in anti-cancer immunity. In research chapter 4, I explored NTP’s effects on tumor-associated NK cell ligands, demonstrating that oxidative stress induced by NTP modulates key immune checkpoints. Several inhibitory ligands, including TIGIT-axis markers and checkpoint CD73, were immediately downregulated, while MICA/B molecules as potent activators of NK cells, were upregulated 24 hours post-treatment. These findings suggest that NTP not only induces direct tumor cytotoxicity but also remodels the tumor immune landscape at various levels, making it a promising immune-modulating therapy. As future perspectives of this work, several concrete directions can be envisioned: (i) NTP’s therapeutic potential could extend beyond HNSCC, serving as an adjuvant strategy to enhance immunogenicity in other malignancies, such as non-small cell lung cancer and triple negative breast cancer, where ICI therapy faces challenges with low and variable response rates; (ii) combining NTP with other endoplasmic reticulum stress-inducing therapies may provide a dual, systemic-local, approach to disbalance cancer’s redox homeostasis, pushing tumor cells over their oxidative threshold while simultaneously triggering stress response pathways linked to ICD; (iii) fundamental questions remain regarding NTP’s immunomodulatory effects, particularly on key immune checkpoints (e.g., PD-1/PD-L1, CTLA-4, and LAG-3) and the direct influence on immune cells within the TME. These opportunities are further explored in review chapter 5, with a focus on intercellular communication via gap junctions. Herein, I provided an extensive overview of their complex role in cancer, demonstrating both pro- and anti-tumoral effects. In addition, the therapeutic potential of targeting gap junctions and their vulnerability to reactive species (ROS) is discussed, while also exploring combinatorial strategies, e.g. combining selective connexin or gap junction modulation with redox-based therapies like NTP, to enhance anti-cancer efficacy. Besides these research aspects, also technical advancement like treatment standardization and sophisticated application tools will be required to integrate NTP into clinical immunotherapy approaches. Taken together, in this thesis, I established NTP as a potent immunogenic adjuvant to standard cancer therapies, with broad implications for enhancing innate and adaptive immune responses. The ability of NTP to sensitize tumors to chemotherapy, modulate immune ligands, and improve anti-tumor immunity positions it as a promising candidate for clinical translation in an adjuvant setting for patients in high need of additional treatment options.